Pathstone Holdings
KRYS icon

Pathstone Holdings’s Krystal Biotech KRYS Stock Holding History

Pathstone Holdings’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$993K Buy
2,672
+431
+19% +$129K ﹤0.01% 1511
2026
Q1 		$579K Sell
2,241
-40
-2% -$10.6K ﹤0.01% 1684
2025
Q4 		$562K Sell
2,281
-2,066
-48% -$435K ﹤0.01% 1702
2025
Q3 		$767K Buy
4,347
+408
+10% +$61.1K ﹤0.01% 1559
2025
Q2 		$541K Sell
3,939
-4,170
-51% -$613K ﹤0.01% 1689
2025
Q1 		$1.46M Buy
8,109
+3,857
+91% +$649K 0.01% 1154
2024
Q4 		$666K Sell
4,252
-795
-16% -$141K ﹤0.01% 1595
2024
Q3 		$919K Buy
+5,047
New +$973K ﹤0.01% 1414

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pathstone Holdings's KRYS Position: Q2 2026 in Review

Pathstone Holdings increased its Krystal Biotech (KRYS) stake by 19% in Q2 2026, buying an estimated $129K and bringing the position to 2,672 shares worth $993K. The position accounts for ﹤0.01% of the portfolio, ranked #1511.

Pathstone Holdings first reported a position in KRYS in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.46M in Q1 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Pathstone Holdings held 2,672 shares of Krystal Biotech worth $993K as of Q2 2026.
  • Pathstone Holdings bought 431 Krystal Biotech shares in Q2 2026, an estimated $129K.
  • Krystal Biotech made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1511 holding.
  • Pathstone Holdings first reported a position in Krystal Biotech in Q3 2024 and has held it in 8 quarters since.
  • Pathstone Holdings's Krystal Biotech position peaked at $1.46M in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.